Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Non-Current Deffered Revenue (2023 - 2024)

Connect Biopharma Holdings (CNTB) has disclosed Non-Current Deffered Revenue for 2 consecutive years, with $632000.0 as the latest value for Q4 2024.

  • Quarterly Non-Current Deffered Revenue rose 56.05% to $632000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $632000.0 through Dec 2024, up 56.05% year-over-year, with the annual reading at $632000.0 for FY2024, 56.05% up from the prior year.
  • Non-Current Deffered Revenue hit $632000.0 in Q4 2024 for Connect Biopharma Holdings, up from $405000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $632000.0 in Q4 2024 to a low of $405000.0 in Q4 2023.